Relapsing-remitting multiple sclerosis is a type of multiple ... RRMS may also progress to secondary progressive MS. SPMS follows an initial pattern of relapses and remissions and then gets ...

Patients with multiple sclerosis (MS) most commonly have a relapsing-remitting course followed eventually by a secondary progressive phase. During this latter period, disability relentlessly ...

Oftentimes, when patients are diagnosed with secondary-progressive MS, it can affect their self-image, and they can grieve over the loss of their former self. And by that, I just mean the loss of ...

Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown that the commonly used high-cholesterol drug simvastatin cannot slow ...

Researchers don’t yet fully understand what causes multiple sclerosis ... can help with secondary progressive multiple sclerosis. There’s currently no specific prevention method for multiple ...

These quiz questions about secondary progressive multiple sclerosis (SPMS) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your ...

And it's been hard on our marriage. I never really understood what secondary progressive MS meant. Having secondary progressive MS is profoundly different from having relapsing/remitting.

"With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

The onset of multiple sclerosis (MS) in older individuals correlates with a higher risk of developing primary progressive MS, faster progression to secondary progressive MS, and increased disability ...

today announced the discovery of new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with nasal foralumab. We believe these findings ...